Search

Search Constraints

You searched for: Author/Creator Pivot, X.

Search Results

22. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. (September 2017)